This research aims to elucidate the intricate relationship between CSF1R and MDSC lipid metabolism, with an overarching goal of appraising the potential therapeutic benefits of a novel nanocarrier, LNCs@CSF1R siRNA, in tandem with anti-PD-1 antibodies for the treatment of colorectal cancer in pre-clinical models. Here, CSF1R is linked to colorectal cancer.